Walleye Capital LLC Invests $444,000 in uniQure (NASDAQ:QURE)

Walleye Capital LLC purchased a new stake in uniQure (NASDAQ:QURE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 90,142 shares of the biotechnology company’s stock, valued at approximately $444,000. Walleye Capital LLC owned approximately 0.18% of uniQure at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its position in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new stake in uniQure in the third quarter worth about $53,000. Vanguard Personalized Indexing Management LLC raised its holdings in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in uniQure during the 3rd quarter valued at about $69,000. Finally, Total Clarity Wealth Management Inc. bought a new position in shares of uniQure in the 2nd quarter valued at about $74,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

QURE stock opened at $7.45 on Monday. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $363.14 million, a PE ratio of -1.50 and a beta of 0.89. The business’s 50-day moving average price is $6.15 and its two-hundred day moving average price is $6.06.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. As a group, research analysts forecast that uniQure will post -3.74 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on QURE shares. Raymond James restated an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price target on shares of uniQure in a research note on Wednesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. The Goldman Sachs Group cut their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, uniQure currently has an average rating of “Hold” and an average target price of $17.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.